IL65915A - Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby - Google Patents

Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby

Info

Publication number
IL65915A
IL65915A IL65915A IL6591582A IL65915A IL 65915 A IL65915 A IL 65915A IL 65915 A IL65915 A IL 65915A IL 6591582 A IL6591582 A IL 6591582A IL 65915 A IL65915 A IL 65915A
Authority
IL
Israel
Prior art keywords
producing
tryptic peptide
methods
specific antibodies
immunologically active
Prior art date
Application number
IL65915A
Other languages
English (en)
Other versions
IL65915A0 (en
Original Assignee
Goldenberg Milton David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldenberg Milton David filed Critical Goldenberg Milton David
Publication of IL65915A0 publication Critical patent/IL65915A0/xx
Publication of IL65915A publication Critical patent/IL65915A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL65915A 1981-06-01 1982-05-31 Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby IL65915A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/269,115 US4468457A (en) 1981-06-01 1981-06-01 Method for producing a CSAp tryptic peptide and anti-CSAp antibodies

Publications (2)

Publication Number Publication Date
IL65915A0 IL65915A0 (en) 1982-08-31
IL65915A true IL65915A (en) 1985-07-31

Family

ID=23025864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL65915A IL65915A (en) 1981-06-01 1982-05-31 Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby

Country Status (9)

Country Link
US (1) US4468457A (fr)
EP (1) EP0066786B1 (fr)
JP (1) JPS58501355A (fr)
AT (1) ATE19792T1 (fr)
AU (1) AU550306B2 (fr)
CA (1) CA1183451A (fr)
DE (1) DE3271119D1 (fr)
IL (1) IL65915A (fr)
WO (1) WO1982004263A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
NO861491L (no) * 1985-04-22 1986-10-23 Hybritech Inc Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser.
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
CA1329119C (fr) * 1988-03-29 1994-05-03 Milton David Goldenberg Therapie faisant appel a des agents cytotoxiques
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999059633A1 (fr) 1998-05-20 1999-11-25 Immunomedics, Inc. Medicament renfermant un anticorps bispecifique antipathogene/anti-chaine invariante de la classe ii du systeme hla
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
EP1247095B1 (fr) 1999-12-06 2008-10-15 Board Of Trustees Of The University Of Illinois Proteines des recepteurs de leucocytes t (tcr) a affinite elevee et procedes correspondants
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
ATE368477T1 (de) * 2000-06-20 2007-08-15 Immunomedics Inc Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1372741B1 (fr) * 2001-03-30 2006-08-09 University of Massachusetts Imagerie de morpholino et therapie
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
CA2514277C (fr) 2003-01-31 2015-01-20 Immunomedics, Inc. Methodes et compositions permettant d'administrer des agents therapeutiques et diagnostiques
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
CA2533878A1 (fr) * 2003-07-29 2005-09-22 Immunomedics, Inc. Conjugues glucidiques fluores
DK2447375T3 (da) 2004-03-31 2019-07-29 Massachusetts Gen Hospital Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål
AU2005244271B2 (en) * 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
EP2674440B1 (fr) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Ensembles bioactifs à base d'immunoglobuline multivalent
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
KR20170014023A (ko) 2006-07-05 2017-02-07 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2009126944A1 (fr) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
US9475049B2 (en) 2009-07-31 2016-10-25 Invisible Sentinel, Inc. Analyte detection devices, multiplex and tabletop devices for detection of analyte, and uses thereof
EP2486049A1 (fr) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Récepteurs de lymphocytes t à chaîne unique humains
CN102612555A (zh) 2009-10-09 2012-07-25 因威瑟堡善迪诺有限公司 用于检测抗原的装置及其应用
WO2013096455A1 (fr) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Méthodes de diagnostic et de traitement d'un cancer associé à kras oncogène
NZ629703A (en) 2012-03-09 2016-05-27 Invisible Sentinel Inc Methods and compositions for detecting multiple analytes with a single signal
EP2855698A4 (fr) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc Ciblage de la voie allant de la glutamine au pyruvate pour traiter un cancer associé à l'oncogène kras
WO2014014518A1 (fr) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Méthodes de traitement, de prévention et de prédiction du risque de développer le cancer du sein
KR102250696B1 (ko) 2012-07-27 2021-05-12 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
WO2014028560A2 (fr) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies
HRP20220399T1 (hr) 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
CA2921619C (fr) 2013-08-19 2021-05-25 Abbott Molecular Inc. Analogues nucleotidiques
WO2015050844A1 (fr) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Procédés de traitement anticancéreux par des composés apparentés à l'atovaquone
DK3071593T3 (da) 2013-11-22 2019-06-11 The Board Of Trustees Of The Univ Of Illionis Modificerede humane t-celle-receptorer med høj affinitet
WO2015149006A2 (fr) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions et procédés de modulation du ciblage autophagique de la ferritine médié par ncoa4
PL3258931T3 (pl) 2015-02-17 2020-12-28 Erasmus University Medical Center Rotterdam Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
EP3316885B1 (fr) 2015-07-01 2021-06-23 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
AU2016326449B2 (en) 2015-09-21 2024-10-31 Aptevo Research And Development Llc CD3 binding polypeptides
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
WO2019046556A1 (fr) 2017-09-01 2019-03-07 East Carolina University Composés, compositions, kits et procédés pour activer des cellules immunitaires et/ou une réponse de système immunitaire
WO2020236818A1 (fr) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Colorants à émission étroite, compositions contenant ces derniers, et méthodes de production et d'utilisation correspondantes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen

Also Published As

Publication number Publication date
EP0066786B1 (fr) 1986-05-14
AU8731882A (en) 1982-12-07
WO1982004263A1 (fr) 1982-12-09
EP0066786A2 (fr) 1982-12-15
AU550306B2 (en) 1986-03-13
DE3271119D1 (en) 1986-06-19
US4468457A (en) 1984-08-28
CA1183451A (fr) 1985-03-05
IL65915A0 (en) 1982-08-31
EP0066786A3 (en) 1983-07-20
ATE19792T1 (de) 1986-05-15
JPS58501355A (ja) 1983-08-18

Similar Documents

Publication Publication Date Title
IL65915A (en) Methods for producing a purified immunologically active tryptic peptide and for producing mono-specific antibodies to peptides prepared thereby
MY8600519A (en) Hybird cell line for producing monoclonal antibody to a human prothymocyte antigen antibody method of preparation of this antibody diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
MY8600517A (en) Hybird cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells antibody method of preparation of this antibody diagnostic anand therapeutic uses and pharmaceutical compositions comprising this antibody
IL86809A (en) Second generation monoclonal antibodies with binding specificity to tag-72, method for detecting human carcinomas utilizing the same, and pharmaceutical compositions containing the same
DE3170352D1 (en) Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody, and methods
ZA802524B (en) Hybrid cell line for producing monoclonal antibody to human helper t cells,antibody,and methods
MY8600535A (en) Monoclonal antibody to human t cells method for preparing it, hybird cell line producing it, therapeutic composition comprising it and diagnostic method using it.
EP0461177A4 (en) Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
AU590656B2 (en) Anti cytomegaloviral human monoclonal antibody and process for its preparation
SE8103198L (sv) Forfarande for framstellning av antikroppar
EP0954529A4 (fr) Antigenes de porphyromonas gingivalis pour le diagnostic et le traitement de periodontites
JPS5657753A (en) Novel glucagon fragment, and its use
ES443969A1 (es) Procedimiento de preparacion de un agente peptidico de regu-lacion de la glucemia.
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
Federspiel et al. Production of monoclonal antibodies specific for African swine fever virus following in vitro primary immunization of mouse splenocytes in the presence of stimulated T lymphocyte supernatants
ES8707862A1 (es) Procedimiento para la obtencion de un anticuerpo monoclonal contra la hormona estimuladroa de foliculos
JPS5344620A (en) Recovering of immobilized vaccine and specific antigen
JPS5234668A (en) Gaseous phase growing process of semiconductor
DE3475309D1 (en) Synthetic peptide, immune globulin and process for immunizing a mammal
Lutz Proctor et al. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population
JPS5239670A (en) Process for synthesizing motilin
PT79232B (en) Process for producing immune interferon and of pharmaceutical compositions containing the same
Deutsch et al. Original antigenic sin at the cellular level—III: Importance of protein carrier in the stimulation process
JPS5326394A (en) Preparation of peptide
JPS6471481A (en) Cell line producing monoclonal antibody and monoclonal antibody produced therefrom